Cargando…
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
BACKGROUND: Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare da...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Medical Biochemists of Serbia, Belgrade
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451228/ https://www.ncbi.nlm.nih.gov/pubmed/34616223 http://dx.doi.org/10.5937/jomb0-31475 |
_version_ | 1784569799353827328 |
---|---|
author | Danese, Elisa Montagnana, Martina Salvagno, Gian Luca Gelati, Matteo Peserico, Denise Pighi, Laura de Nitto, Simone Henry, Brandon M. Porru, Stefano Lippi, Giuseppe |
author_facet | Danese, Elisa Montagnana, Martina Salvagno, Gian Luca Gelati, Matteo Peserico, Denise Pighi, Laura de Nitto, Simone Henry, Brandon M. Porru, Stefano Lippi, Giuseppe |
author_sort | Danese, Elisa |
collection | PubMed |
description | BACKGROUND: Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare data of five commercial anti-SARS-CoV2 immunoassays after administration of an mRNA vaccine. METHODS: Venous blood was collected from three healthcare workers, receiving a double (30 g) dose of BNT162b2 mRNA Covid-19 vaccine (Comirnaty, Pfizer), on the day of the first vaccine dose and then at fixed intervals for the following 2 months. Anti-SARS-CoV-2 neutralizing antibody response was assayed with Roche Total Ig anti-RBD (receptor binding domain), DiaSorin TrimericS IgG (spike trimer), Beckman Coulter IgG anti-RBD, SNIBE IgG anti-RBD and Technogenetics IgG anti-N/S1. RESULTS: A total number of 45 samples were drawn at the end of the 2-month study period. The Spearman's correlations of absolute anti-SARS-CoV-2 antibodies were always excellent (all p<0.001), comprised between 0.967-0.994. Satisfactory results were also observed when absolute antiSARS-CoV-2 antibodies values of the five methods were compared with the mean consensus value, with correlations always higher than 0.979 (all p<0.001). The agreement of anti-SARS-CoV-2 antibodies positivity versus the consensus median positivity ranged between 0.764 and 1.000 (always p<0.001), but become always >0.900 after readjustment of one assay cutoff. CONCLUSIONS: All the immunoassays evaluated in this study appear suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination. |
format | Online Article Text |
id | pubmed-8451228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Society of Medical Biochemists of Serbia, Belgrade |
record_format | MEDLINE/PubMed |
spelling | pubmed-84512282021-10-05 Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA Danese, Elisa Montagnana, Martina Salvagno, Gian Luca Gelati, Matteo Peserico, Denise Pighi, Laura de Nitto, Simone Henry, Brandon M. Porru, Stefano Lippi, Giuseppe J Med Biochem Original Paper BACKGROUND: Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare data of five commercial anti-SARS-CoV2 immunoassays after administration of an mRNA vaccine. METHODS: Venous blood was collected from three healthcare workers, receiving a double (30 g) dose of BNT162b2 mRNA Covid-19 vaccine (Comirnaty, Pfizer), on the day of the first vaccine dose and then at fixed intervals for the following 2 months. Anti-SARS-CoV-2 neutralizing antibody response was assayed with Roche Total Ig anti-RBD (receptor binding domain), DiaSorin TrimericS IgG (spike trimer), Beckman Coulter IgG anti-RBD, SNIBE IgG anti-RBD and Technogenetics IgG anti-N/S1. RESULTS: A total number of 45 samples were drawn at the end of the 2-month study period. The Spearman's correlations of absolute anti-SARS-CoV-2 antibodies were always excellent (all p<0.001), comprised between 0.967-0.994. Satisfactory results were also observed when absolute antiSARS-CoV-2 antibodies values of the five methods were compared with the mean consensus value, with correlations always higher than 0.979 (all p<0.001). The agreement of anti-SARS-CoV-2 antibodies positivity versus the consensus median positivity ranged between 0.764 and 1.000 (always p<0.001), but become always >0.900 after readjustment of one assay cutoff. CONCLUSIONS: All the immunoassays evaluated in this study appear suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination. Society of Medical Biochemists of Serbia, Belgrade 2021-09-03 2021-09-03 /pmc/articles/PMC8451228/ /pubmed/34616223 http://dx.doi.org/10.5937/jomb0-31475 Text en 2021 Elisa Danese, Martina Montagnana, Gian Luca Salvagno, Matteo Gelati, Denise Peserico, Laura Pighi, Nitto Simone de, Brandon M. Henry, Stefano Porru, Giuseppe Lippi, published by CEON/CEES https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License. |
spellingShingle | Original Paper Danese, Elisa Montagnana, Martina Salvagno, Gian Luca Gelati, Matteo Peserico, Denise Pighi, Laura de Nitto, Simone Henry, Brandon M. Porru, Stefano Lippi, Giuseppe Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title | Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title_full | Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title_fullStr | Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title_full_unstemmed | Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title_short | Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA |
title_sort | comparison of five commercial anti-sars-cov-2 total antibodies and igg immunoassays after vaccination with bnt162b2 mrna |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451228/ https://www.ncbi.nlm.nih.gov/pubmed/34616223 http://dx.doi.org/10.5937/jomb0-31475 |
work_keys_str_mv | AT daneseelisa comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT montagnanamartina comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT salvagnogianluca comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT gelatimatteo comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT pesericodenise comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT pighilaura comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT denittosimone comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT henrybrandonm comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT porrustefano comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna AT lippigiuseppe comparisonoffivecommercialantisarscov2totalantibodiesandiggimmunoassaysaftervaccinationwithbnt162b2mrna |